Health Care Industry
Industry: Email Alert RSS FeedLeaders seek new strategies to strengthen generic industry
Drug Store News, August 18, 1997 by Ken Rankin
The most celebrated, and controversial, of these petitions was filed by Wyeth-Ayerst in an effort to block FDA approval of generic competition for the company's Premarin (conjugated estrogen) product.
Although Premarin has been off patent for more than a generation, difficulties in synthesizing the complex combination of estrogens in the drug have kept lower-cost generic versions off pharmacy shelves. As a result, Wyeth-Ayerst has enjoyed a period of market exclusivity that has lasted decades beyond Premarin's patent protection.
Scientists at Duramed believed they had finally solved the puzzle two years ago, and filed an Abbreviated New Drug Application seeking FDA approval to market a generic equivalent.
Most RecentHealth Care Articles
Before the FDA could rule on that application, however, Wyeth-Ayerst challenged the approval through a citizens petition that raised questions about whether the synthetic conjugated estrogen developed for generic distribution contained all of the active ingredients in the original product.
An FDA advisory panel was unable to resolve the controversy, and, after chewing over the issue for more than a year, the FDA rejected the application.
Generic drug industry leaders responded to the FDA's ruling with outrage and frustration, calling the FDA's refusal to approve a generic form of Premarin a "politically motivated decision." GPIA chairman Marvin Samson said, "There is no supportable scientific data to justify the FDA's position."
But, even as they chastised the agency publicly, generic drug industry leaders spent much of the past year working to build congressional support for higher levels of funding for the FDA's activities. At a minimum, the industry is hoping to squeeze out at least $1 million in additional funds to finance an expansion of the FDA's Office of Generic Drugs and speed the approval of new generic medicines. While the agency's final budget had not cleared Congress at press time, the version passed by the House Appropriations Committee last month does contain the extra OGD funding.
State challenges
The generic drug industry also faced a series of challenges at the state level this year, including an aggressive lobbying campaign by DuPont Merck to secure legislation limiting generic substitution for so-called narrow therapeutic index drugs, such as Coumadin.
Although opposition from both the generic drug industry and retail pharmacy groups killed prospects for Narrow Therapeutic Index bills in several states, lawmakers in Virginia, North Carolina and Texas enacted legislation placing restrictions on the right of pharmacists to dispense generic substitutes for narrow therapeutic index products.
A potentially even more serious problem for generic pharmaceutical manufacturers involves proposals by branded drug makers to seek legislative revisions in the 1984 Waxman-Hatch Act, the landmark federal law credited with streamlining the approval process for generic medicines. One possible change that worries industry leaders would enable manufacturers of brand name drugs to secure more favorable patent term extensions to offset the period of patent life lost during the FDA approval process. A change in the formula for calculating such patent restorations could delay the introduction of competing generics by several months or even years.
Brought to you by CBS MoneyWatch.com
- Best- and Worst-Paid College Degrees
- 6 Things You Should Never Do on Twitter or Facebook
- How Much Sleep Do You Really Need?
- 6 Big Myths about Gas Mileage
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Content provided in partnership with
Most Recent Health Articles
Most Recent Health Publications
Most Popular Health Articles
- 50 home remedies that work: these safe, fast, and effective fixes will relieve what ails you - Cover Story
- Detox in 7 days: a detoux diet can help you shed up to 10 pounds and leave you feeling terrific. Our weeklong plan shows you how to lose the weight and keep it off - Cover story
- Treat sinusitis naturally: breath easy and relieve sinus pressure with these remedies - Quick Fixes and Long-Term Solutions
- Make running easier: with this unique 'pose running' technique, you'll learn to actually enjoy your fat-burning sessions
- All about nightshades: explore the hidden hazards of your favorite food with macrobiotic nutritionist Lino Stanchich


